Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318602 · ClinicalTrials.gov registry record · Phase 3
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
A Phase 3 study, sponsored by INSYS Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT02318602 is a Phase 3 study that has completed, run by INSYS Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT02318602, a Phase 3 study, has completed, sponsored by INSYS Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). All participants have rolled over from previous trials: INS011-14-029 (NCT02324673) and INS011-15-054 (NCT02551731).
Interventions
- DRUG Cannabidiol Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-01-08 |
| Est. Completion | 2017-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318602
The ClinicalTrials.gov registry entry for NCT02318602 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is INSYS Therapeutics, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol Oral Solution is the first listed.
NCT02318602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02318602 about?
NCT02318602 is a clinical study titled "Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder". This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). All participants have rolled ...
What is the current status of trial NCT02318602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2016-01-08. Estimated completion is 2017-06-22.
What interventions are being tested in trial NCT02318602?
The interventions under investigation include: Cannabidiol Oral Solution (DRUG).
Who is sponsoring clinical trial NCT02318602?
This trial is sponsored by INSYS Therapeutics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.